title: Human leukocyte antigen mismatch and other factors affecting cryopreserved allograft valve function.
abstract: The causes of cryopreserved allograft heart valve degeneration are poorly understood. We investigated HLA mismatch and other factors implicated in allograft valve degeneration. For this study we recruited 110 adult recipients of allograft heart valves who underwent surgery between June 1998 and March 2003 in the state of Victoria, Australia. Recipients and donors were HLA typed using serological and molecular methods. Valve function at most recent echocardiographic follow-up was examined for an association with the following variables using univariate and multivariate methods: HLA-A,-B, and -DR donor-recipient mismatch; HLA class I mismatch; total HLA mismatch; valve ischemic time; recipient age; donor age; ABO blood group donor-recipient match; and allograft size. Mean recipient age was 45 years (18-75 years), 75% were men. Seventy-four pulmonary (62 Ross procedure) and 36 aortic allografts were examined. Median valve ischemic time was 31 hours, range 20-48 hours. Echocardiographic follow-up was complete at a mean of 41 (+/-18) months, range 6-85 months. At univariate analysis longer ischemic time and younger recipient age were associated with valve dysfunction. HLA-A, -B, or DR mismatch, HLA class I mismatch, total HLA mismatch, donor age, ABO mismatch, and allograft size were not associated with valve dysfunction. Only younger recipient age remained significant at multivariate analysis. In conclusion, longer ischemic times and younger patient age predicted valve dysfunction at a mean of 3 years follow-up. Recipient age remained the strongest predictor of valve dysfunction. These results indicate that allograft ischemic times should be minimized.
authors.affiliation: Department of Cardiothoracic Surgery, St. Vincent's Hospital, Melbourne, Australia. cheng-hon.yap@svhm.org.au
authors.forename: Cheng-Hon
authors.initials: CH
authors.lastname: Yap
authors.forename: Peter D
authors.initials: PD
authors.lastname: Skillington
authors.forename: George
authors.initials: G
authors.lastname: Matalanis
authors.forename: Bruce B
authors.initials: BB
authors.lastname: Davis
authors.forename: Brian D
authors.initials: BD
authors.lastname: Tait
authors.forename: Fiona
authors.initials: F
authors.lastname: Hudson
authors.forename: Lyn
authors.initials: L
authors.lastname: Ireland
authors.forename: Ian
authors.initials: I
authors.lastname: Nixon
authors.forename: Michael
authors.initials: M
authors.lastname: Yii
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D015925:Cryopreservation; D005260:Female; D006680:HLA Antigens; D006349:Heart Valve Diseases / Q000601:surgery*; D006350:Heart Valve Prosthesis; D006351:Heart Valves / Q000601:surgery*; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D006650:Histocompatibility Testing; D006801:Humans; D007511:Ischemia; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014184:Transplantation, Homologous
chemical_list: D006680:HLA Antigens; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II